APA (7th ed.) Citation

S, Y., H, K., K, H., Y, K., K, P., Y, K., . . . M, F. (2026). Study protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancer. BMC cancer. https://doi.org/10.1186/s12885-026-16478-1

Chicago Style (17th ed.) Citation

S, Yuki, et al. "Study Protocol of the C-SOLVE (JACCRO GC-12) Trial; a Randomized, Non-comparative Phase II Trial of CapeOX or SOX Plus Zolbetuximab in HER2-negative, CLDN18.2-positive Unresectable Advanced Gastric or Esophagogastric Junction Cancer." BMC Cancer 2026. https://doi.org/10.1186/s12885-026-16478-1.

MLA (9th ed.) Citation

S, Yuki, et al. "Study Protocol of the C-SOLVE (JACCRO GC-12) Trial; a Randomized, Non-comparative Phase II Trial of CapeOX or SOX Plus Zolbetuximab in HER2-negative, CLDN18.2-positive Unresectable Advanced Gastric or Esophagogastric Junction Cancer." BMC Cancer, 2026, https://doi.org/10.1186/s12885-026-16478-1.